-
Fosinopril sodium in ACE Inhibitor Research
2026-09-14
Fosinopril sodium gives hypertension research a mechanistically distinctive ACE inhibitor anchor for separating direct enzyme inhibition, prodrug activation, blood pressure reduction, and renal responses. This workflow-focused guide covers assay selection, cardiovascular disease model design, solution handling, and troubleshooting for more reproducible translational studies.
-
MIR9 Epigenetics and FGFR1/CDK6 in ALL
2026-09-14
Rodriguez-Otero et al. linked MIR9-family hypermethylation with reduced microRNA expression, adverse outcomes, and activation of FGFR1 and CDK6 signaling in acute lymphoblastic leukaemia. The study combines patient methylation and survival data with inhibitor experiments, providing a mechanistic framework for biomarker-guided investigation of epigenetic regulation and downstream pathway dependence.
-
Moxifloxacin: Applied DNA Gyrase Research Workflows
2026-09-13
Moxifloxacin supports complementary antibacterial, cell-viability, and antibiotic-response studies rather than a single assay format. This guide connects DNA gyrase biology with practical stock preparation, retinal ganglion cell workflows, metabolic-response interpretation, and troubleshooting strategies.
-
Omeprazole (A2845): Research Workflow Guide
2026-09-12
Omeprazole (SKU A2845) provides a research-grade H+,K+-ATPase inhibitor for controlled gastric acid secretion and antiulcer activity studies. It is intended for laboratory use only; its water and ethanol insolubility, solution-storage limitations, and conditional IC50 values require deliberate stock preparation and assay-specific validation.
-
Caffeic Acid Phenethyl Ester (CAPE) Workflows
2026-09-12
Caffeic Acid Phenethyl Ester (CAPE) is a practical NF-κB pathway probe for connecting inflammatory signaling, neurodegeneration, angiogenesis, and tumor invasion assays. This workflow emphasizes solvent control, orthogonal readouts, and careful separation of NF-κB effects from Stat3-linked biology.
-
Bufalin Targets STK33 in Triple-Negative Breast Cancer
2026-09-11
The 2025 Advanced Science study identifies serine/threonine kinase 33 (STK33) as a direct binding target and putative degradation substrate of Bufalin in triple-negative breast cancer. By combining target-discovery, biochemical, genetic, animal, and patient-derived organoid models, the work connects Bufalin–STK33 binding to disruption of the STK33–HSP90 complex, CCAR1 regulation, and reduced tumor growth.
-
Caspase-3 Colorimetric Assay Kit Guide
2026-09-11
The Caspase-3 Colorimetric Assay Kit (SKU K2008) measures DEVD-dependent caspase-3 activity in biological lysates by converting substrate cleavage into p-nitroaniline absorbance at 405 or 400 nm. It is suited to comparative apoptosis assays and caspase activity measurement, but it should not be used alone to prove apoptosis, identify the activation route, or establish exclusive caspase-3 activity.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-10
FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin probe for visualizing accessible α-D-glucose and α-D-mannose residues on cell-surface glycoproteins and glycolipids. It supports immunofluorescence staining, microscopy, and flow cytometry carbohydrate detection, but it should not be treated as a universal cell stain or a substitute for target-specific molecular identification.
-
Bufalin Workflows for TNBC Research
2026-09-10
Bufalin enables a practical bridge between phenotype-first oncology assays and target-level validation, with workflows spanning apoptosis, STK33 degradation, and organoid testing. This guide emphasizes dose control, orthogonal evidence, and troubleshooting so researchers can distinguish general cytotoxicity from mechanism-linked activity.
-
SB 431542 in Long-Term Muscle Grafts
2026-09-09
SB 431542 is a selective ALK5 inhibitor for dissecting TGF-β signaling during stem-cell-derived muscle regeneration studies. This article connects its Smad2-directed mechanism with long-term human myogenic graft analysis and practical assay design.
-
O-GlcNAcylation Rewires Glycolysis in Wnt Bone Formation
2026-09-09
The reference study shows that O-GlcNAcylation is a necessary mediator of Wnt-stimulated osteoblastogenesis, linking Wnt signaling to aerobic glycolysis through stabilization of PDK1 at Ser174. Its findings position nutrient-sensitive protein modification as a mechanistic control point in bone formation and fracture healing, while suggesting experimental strategies for dissecting O-GlcNAc-dependent signaling.
-
Tp47 Drives Macrophage Inflammatory Senescence
2026-09-08
The reference study identifies a mechanistic link between the Treponema pallidum protein Tp47, PKM2-dependent metabolic reprogramming, and inflammatory senescence in macrophages. Its findings connect PKM2 stabilization, lactate production, EIF2AK2 phosphorylation, NLRP3 inflammasome activity, and pyroptosis, while suggesting a framework for combining metabolic, inflammatory, and senescence readouts.
-
HMGB1 for Early Diabetic Nephropathy Monitoring
2026-09-07
A 2024 iScience study used quantitative serum proteomics, Mfuzz clustering, and WGCNA to identify proteins associated with diabetic nephropathy progression. HMGB1 showed particular promise as an early monitoring candidate, although clinical validation and assay standardization remain necessary before routine use.
-
I-BET-762: A BET Inhibitor for Mechanistic Assays
2026-09-07
I-BET-762 is a selective BET inhibitor for dissecting transcriptional control, inflammation, and ferroptosis sensitization. This article provides an assay-centered framework for connecting BRD4 inhibition, ROS accumulation, FSP1 regulation, and LPS-responsive gene expression without overinterpreting cell-based results.
-
Streptozotocin Workflows for Diabetes Research
2026-09-05
Streptozotocin enables controlled β-cell injury, hyperglycemia, and downstream studies of diabetic complications. This practical guide connects STZ model design with neuropathy assays, TBK1–microglia biology, and troubleshooting strategies that improve interpretability.